Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bridget Oboyle Jordan

Nurse Practitioner, Pediatrics West Linn, OR Nurse Practitioner

NPI 1972519429 CMS profile 10885745

21900 Willamette Dr Ste 202, West Linn, OR 97068

Open in the dashboard

General payments

$1,685

104 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bridget Oboyle Jordan of West Linn, OR is reported in the CMS Open Payments database as having received $1,685 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $163 14
2024 General $297 14
2023 General $444 31
2022 General $673 39
2021 General $107 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bridget Oboyle Jordan
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Bridget Oboyle Jordan were reported at $163. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Bridget Oboyle Jordan Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $107 $60 $23–$142 $132
2022 $673 $72 $27–$161 $149
2023 $444 $89 $35–$185 $160
2024 $297 $93 $34–$199 $164
2025 $163 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Supernus Pharmaceuticals, Inc. $744 61 payments
  2. Otsuka America Pharmaceutical, Inc. $433 16 payments
  3. Corium, Inc. $128 7 payments
  4. Ironshore Pharmaceuticals Inc. $106 6 payments
  5. AbbVie, Inc. $55 3 payments
  6. Alkermes, Inc. $51 3 payments
  7. Lundbeck LLC $47 2 payments
  8. Tempus AI, Inc $28 1 payment
  9. Noven Therapeutics, LLC $23 1 payment
  10. Teva Pharmaceuticals USA, Inc. $20 1 payment
  11. Other $51 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,685 104 payments
Products named General payments · program years 2021–2025
  1. QELBREE Psychology $426 39 payments
  2. REXULTI $408 14 payments
  3. Qelbree Viloxazine Hydrochloride $281 20 payments
  4. Azstarys $128 7 payments
  5. ABILIFY MAINTENA $80 4 payments
  6. JORNAY PM Central Nervous System Stimulant $58 3 payments
  7. VRAYLAR $55 3 payments
  8. LYBALVI Cns $51 3 payments
  9. LYBALVI Cns $51 3 payments
  10. JORNAY PM Central Nervous Stimulant ADHD $48 3 payments
  11. Other $284 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record